Truist Lowers PT on PROCEPT BioRobotics Corporation (PRCT) to $50 From $64, Keeps a Buy Rating

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the best small cap stocks with the highest upside. On October 15, Truist slashed the price target on PROCEPT BioRobotics Corporation (NASDAQ:PRCT) to $50 from $64 while maintaining a Buy rating on the shares.

The rating update came as part of a broader research note previewing the fiscal Q3 results in the MedTech sector. The firm told investors that it expects to see “healthy” Q3 earnings and revenue across the firms in its coverage, but is also bracing for “stock volatility”.

Truist is more inclined towards “cleaner” names that have less perceived controversy heading into this quarter.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is a commercial-stage surgical robotics company that develops transformative solutions for urology. The company manufactures and sells the AquaBeam Robotic System, which is an image-guided, surgical robotic system used in minimally invasive urologic surgery.

While we acknowledge the potential of PRCT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.